Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
303.2 INR | +1.35% | -4.95% | -25.35% |
Mar. 19 | Venus Remedies Secures Marketing Authorizations in Ukraine for Three Oncology Drugs | MT |
Mar. 08 | Venus Remedies Gets Ukraine's Marketing Approval for Three Oncology Products | MT |
Sales 2022 | 5.99B 71.72M | Sales 2023 | 5.56B 66.56M | Capitalization | 2.16B 25.94M |
---|---|---|---|---|---|
Net income 2022 | 407M 4.88M | Net income 2023 | 266M 3.19M | EV / Sales 2022 | 0.6 x |
Net cash position 2022 | 4.11M 49.19K | Net cash position 2023 | 291M 3.48M | EV / Sales 2023 | 0.34 x |
P/E ratio 2022 |
8.71
x | P/E ratio 2023 |
8.15
x | Employees | 998 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 52.79% |
1 day | +1.35% | ||
1 week | -4.95% | ||
Current month | -7.45% | ||
1 month | -10.78% | ||
3 months | -21.97% | ||
6 months | -6.63% | ||
Current year | -25.35% |
Managers | Title | Age | Since |
---|---|---|---|
Ashutosh Jain
CEO | Chief Executive Officer | 47 | 07-04-30 |
Pawan Chaudhary
CHM | Chairman | 60 | 89-09-14 |
Jitendra Singh
ADM | Chief Administrative Officer | - | 98-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Gilbert Wenzel
BRD | Director/Board Member | 67 | - |
Peeyush Jain
BRD | Director/Board Member | 52 | - |
Ashutosh Jain
CEO | Chief Executive Officer | 47 | 07-04-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 303.2 | +1.35% | 7 588 |
24-05-09 | 299.2 | -2.59% | 25,723 |
24-05-08 | 307.2 | -1.06% | 34,539 |
24-05-07 | 310.4 | -0.86% | 24,658 |
24-05-06 | 313.2 | -1.85% | 25,010 |
Delayed Quote NSE India S.E., May 10, 2024 at 02:10 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
+32.36% | 695B | |
+26.51% | 568B | |
-4.40% | 361B | |
+19.46% | 330B | |
+3.50% | 283B | |
+16.34% | 239B | |
+6.68% | 204B | |
-9.08% | 198B | |
+8.62% | 168B |
- Stock Market
- Equities
- VENUSREM Stock
- VENUSREM Stock